PriceTargets.com logo

CNSX:MARI - Maricann Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: ∞
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 03/14/2019 08:48 AM ET
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Maricann Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MARI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MARI

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$5.00
▲ +∞ Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Maricann Group in the last 3 months. The average price target is $5.00, with a high forecast of $6.00 and a low forecast of $4.00. The average price target represents a ∞ upside from the last price of $0.00.

Buy

The current consensus among 2 polled investment analysts is to buy stock in Maricann Group. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/17/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/9/2021Raymond JamesBoost Price TargetOutperform$5.50 ➝ $6.00
i
5/20/2021Raymond JamesSet Price TargetOutperform$5.50
i
5/6/2021Raymond JamesSet Price TargetOutperform$5.50
i
4/21/2021Raymond JamesSet Price TargetOutperform$5.50
i
12/7/2020Canaccord GenuitySet Price TargetSpeculative Buy$4.00
i
8/20/2018Canaccord GenuityLower Price Target$4.25 ➝ $3.75
i
(Data available from 6/16/2016 forward)
Maricann Group logo
Maricann Group Inc, formerly Danbel Industries Corporation, is a Canada-based integrated producer and distributor of marijuana for medical purposes. As one of approximately 43 companies with a federal license to cultivate cannabis and one of approximately 30 independent licensed producers with a federal license to process and distribute cannabis, the Company's services a patient base with more than 8,000 registered patients. The Company is undertaking an expansion of the cultivation and support facilities to support existing and future patient growth.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

682,578 shs

Average Volume

142,686 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Maricann Group?

The following sell-side analysts have issued research reports on Maricann Group in the last twelve months: Canaccord Genuity, and Raymond James.
View the latest analyst ratings for MARI.

What is the current price target for Maricann Group?

2 Wall Street analysts have set twelve-month price targets for Maricann Group in the last year. Their average twelve-month price target is $5.00. Raymond James has the highest price target set, predicting MARI will reach $6.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $4.00 for Maricann Group in the next year.
View the latest price targets for MARI.

What is the current consensus analyst rating for Maricann Group?

Maricann Group currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MARI will outperform the market and that investors should add to their positions of Maricann Group.
View the latest ratings for MARI.

How do I contact Maricann Group's investor relations team?

Maricann Group's physical mailing address is 845 Harrington Crt Unit 3, BURLINGTON, ON L7N 3P3, Canada. The company's listed phone number is +1-289-2886284. The official website for Maricann Group is www.maricann.com.